Unicycive Therapeutics Faces Class Action Over Manufacturing Oversight

The legal action follows a sharp market reaction on June 30, 2026, when Unicycive disclosed that the FDA had issued a Complete Response Letter regarding its oxylanthanum carbonate application. Shares of UNCY dropped $3.01—a 39.1% decline—after the company revealed the rejection stemmed from manufacturing deficiencies previously identified in 2025. Plaintiffs contend the company misled shareholders by claiming the application was on track without conducting required audits of the vendor facility.

According to the complaint, the company resubmitted its drug application based on assumptions of progress rather than verified inspections. Joseph E. Levi of Levi & Korsinsky, the firm representing the investors, stated that shareholders are entitled to test the claim that the company bypassed essential compliance checks. Investors who acquired stock during the specified period may be eligible for the class, regardless of whether they currently hold the shares. Those seeking to serve as lead plaintiff must submit their applications by November 2, 2026, though class members who choose not to take this role may still participate in potential recoveries.